Mediators of Inflammation

Holding the Inflammatory System in Check: TLRs and NLRs


Status
Published

Lead Editor

1Duke University Medical Center, Durham, USA

2Virginia Tech, Blacksburg, USA

3National Institute of Environmental Health Sciences (NIEHS), North Carolina, USA


Holding the Inflammatory System in Check: TLRs and NLRs

Description

Aberrant inflammation has gained much attention in the field of immunology in the recent years due to its role in not only autoimmune disease development but also cancer oncogenesis. Nucleotide-binding oligomerization domain receptors (NLRs) and Toll-like Receptors (TLRs) are key regulators of innate immune responses. TLR and NLR signaling pathways have been shown to play an important role in disease development and exacerbation. Targeting of these receptors has shown promise in preclinical studies of autoimmune disorders and cancer. Recent clinical trials have been initiated to determine the efficacy of compounds targeting NLR and TLR pathways in improving disease outcomes.

The potential of NLR and TLR genes as regulators of inflammatory disorders has undergone extensive preclinical investigation. The signaling pathways for many of these receptors have been well-studied and are now better understood. Major challenges remain in potential ways to target these receptors at various stages of disease development and discover effective therapeutics.

We solicit high quality, original research articles, and review articles centered on research and development of NLR and TLR based therapies in the field of inflammation. We are particularly interested in manuscripts that report the clinical applications of approved or investigational drugs targeting NLR and TLR pathways in various fields of medicine (autoimmunity, oncology, cardiovascular, virology, etc.) with emphasis on efficacy and overall response. Reviews that discuss recent discoveries in basic research and summarize current clinical efforts and outcomes are encouraged.

Potential topics include, but are not limited to:

  • Clinical studies
  • Preclinical efficacy studies of NLR and TLR therapeutics in animal models
  • Mechanistic studies investigating new potential roles of these receptors in cell activation
  • Studies on combination therapies

Articles

  • Special Issue
  • - Volume 2016
  • - Article ID 8156816
  • - Editorial

Holding the Inflammatory System in Check: TLRs and NLRs

Eda K. Holl | Irving C. Allen | Jennifer Martinez
  • Special Issue
  • - Volume 2016
  • - Article ID 3481371
  • - Review Article

Deubiquitinases: Novel Therapeutic Targets in Immune Surveillance?

Gloria Lopez-Castejon | Mariola J. Edelmann
  • Special Issue
  • - Volume 2016
  • - Article ID 7694921
  • - Research Article

Effect of Toll-Like Receptor 4 on Synovial Injury of Temporomandibular Joint in Rats Caused by Occlusal Interference

Jingjing Kong | Yingying Yang | ... | Ping Ji
  • Special Issue
  • - Volume 2016
  • - Article ID 9848263
  • - Research Article

Caspase-11 Modulates Inflammation and Attenuates Toxoplasma gondii Pathogenesis

Sheryl L. Coutermarsh-Ott | John T. Doran | ... | Irving C. Allen
  • Special Issue
  • - Volume 2016
  • - Article ID 8175898
  • - Research Article

Maternal Vitamin D Level Is Associated with Viral Toll-Like Receptor Triggered IL-10 Response but Not the Risk of Infectious Diseases in Infancy

Sui-Ling Liao | Shen-Hao Lai | ... | Jing-Long Huang
  • Special Issue
  • - Volume 2016
  • - Article ID 2180417
  • - Review Article

Holding the Inflammatory System in Check: TLRs and Their Targeted Therapy in Asthma

Zhiyong Dong | Lingxin Xiong | ... | Fang Wang
  • Special Issue
  • - Volume 2016
  • - Article ID 6373506
  • - Research Article

Nonessential Role for the NLRP1 Inflammasome Complex in a Murine Model of Traumatic Brain Injury

Thomas Brickler | Kisha Gresham | ... | Michelle H. Theus
Mediators of Inflammation
 Journal metrics
Acceptance rate36%
Submission to final decision53 days
Acceptance to publication29 days
CiteScore6.000
Impact Factor3.758
 Submit